MNOV
MediciNova, Inc.·Healthcare
1.49
4.930%(+0.07)
Market ClosedLast Updated: — ET
52W L: $1.1752W H: $1.96
MNOV NEWS
defenseworld.net
3d ago
MediciNova (NASDAQ:MNOV) Shares Cross Above 200 Day Moving Average – Here’s What Happened
MediciNova, Inc. (NASDAQ: MNOV - Get Free Report) crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $1.43 and traded as high as $1.43. MediciNova shares last traded at $1.42, with a volume of 18,096 shares changing hands. Analyst Upgrades and Downgrades A number of brokerages
globenewswire.com
Mar 16
MediciNova to Participate at the 38th Annual ROTH Conference
LA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer will participate at the 38th Annual ROTH Conference. The conference is being held on March 22 – 24, 2026 at The Ritz-Carlton Laguna Niguel in Dana Point, CA.
defenseworld.net
Feb 26
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Shares of MediciNova, Inc. (NASDAQ: MNOV - Get Free Report) have earned an average rating of "Moderate Buy" from the five brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, one has issued a buy rating and two
globenewswire.com
Jan 29
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of the end of January 2026, 12 sites in the US are activated and 100 patients have been enrolled in the SEANOBI study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS; NCT 06743776) representing 50% of the planned 200-enrollment, evaluating MN‑166 (ibudilast) in patients with amyotrophic lateral sclerosis (ALS).
